Table 2.
Association between intratumoral lymphatic vessel density and clinicopathologic variables in oral squamous cell carcinomas. A.C.Camargo Cancer Hospital. São Paulo, Brazil
| Variable | Intratumoral lymphatic vessel density | |||||
|---|---|---|---|---|---|---|
| Sequential analysis | p value | Hot spot evaluation | p value | |||
| Low | High | Low | High | |||
| Gender | ||||||
|
Male Female |
43 (86.0%) 07 (14.0%) |
25 (67.6%) 12 (32.4%) |
0.040 |
38 (82.6%) 08 (17.4%) |
30 (73.2%) 11 (26.8%) |
0.288 |
| Ethnic group | ||||||
|
White Not white |
47 (94.0%) 03 (6.0%) |
33 (89.2%) 04 (10.8%) |
0.452 |
44 (95.7%) 02 (4.3%) |
36 (87.8%) 05 (12.2%) |
0.247 |
| Age | ||||||
|
≤ 59 years > 59 years |
28 (56.0%) 22 (44.0%) |
17 (45.9%) 20 (54.1%) |
0.354 |
25 (54.3%) 21 (45.7%) |
20 (48.8%) 21 (51.2%) |
0.604 |
| Tobacco# | ||||||
|
No Yes |
04 (8.5%) 43 (91.5%) |
05 (14.7%) 29 (85.3%) |
0.481 |
05 (11.6%) 38 (88.450 |
04 (10.5%) 34 (89.5%) |
1.000 |
| Alcohol# | ||||||
|
No Yes |
08 (17.0%) 39 (83.0%) |
07 (20.6%) 27 (79.4%) |
0.683 |
08 (18.6%) 35 (81.4%) |
07 (18.4%) 31 (81.6%) |
0.983 |
| Tumor site | ||||||
|
Tongue Floor of mouth |
34 (68.0%) 16 (32.0%) |
26 (70.3%) 11 (29.7%) |
0.821 |
31 (67.4%) 15 (32.6%) |
29 (70.7%) 12 (29.3%) |
0.737 |
| T stage | ||||||
|
T1 T2 |
19 (38.0%) 31 (62.0%) |
09 (24.3%) 28 (75.7%) |
0.177 |
18 (39.1%) 28 (60.9%) |
10 (24.4%) 31 (75.6%) |
0.142 |
| Local recurrence | ||||||
|
No Yes |
41 (82.0%) 09 (18.0%) |
31 (83.8%) 06 (16.2%) |
0.828 |
37 (80.4%) 09 (19.6%) |
35 (85.4%) 06 (14.6%) |
0.543 |
| Regional recurrence | ||||||
|
No Yes |
45 (90.0%) 05 (10.0%) |
28 (75.7%) 09 (24.3%) |
0.072 |
42 (91.3%) 04 (8.7%) |
31 (75.6%) 10 (24.4%) |
0.047 |
| Lymphatic embolization | ||||||
|
No Yes |
38 (76.0%) 12 (24.0%) |
24 (64.9%) 13 (35.1%) |
0.257 |
36 (78.3%) 10 (21.75) |
26 (63.4%) 15 (36.6%) |
0.127 |
| Blood embolization | ||||||
|
No Yes |
43 (86.0%) 07 (14.0%) |
32 (86.5%) 05 (13.5%) |
0.948 |
39 (84.8%) 07 (15.2%) |
36 (87.8%) 05 (12.2%) |
0.683 |
| Perineural infiltration | ||||||
|
No Yes |
26 (52.0%) 24 (48.0%) |
17 (45.9%) 20 (54.1%) |
0.577 |
25 (54.3%) 21 (45.7%) |
18 (43.9%) 23 (56.1%) |
0.331 |
| Muscular infiltration | ||||||
|
No Yes |
11 (22.0%) 39 (780%) |
05 (13.5%) 32 (86.5%) |
0.312 |
10 (21.7%) 36 (78.3%) |
06 (14.6%) 35 (85.4%) |
0.393 |
| Salivary gland infiltration | ||||||
|
No Yes |
34 (68.0%) 16 (32.0%) |
24 (64.9%) 13 (35.1%) |
0.759 |
33 (71.7%) 13 (28.3%) |
25 (61.0%) 16 (39.0%) |
0.288 |
| Lymph-nodal status# | ||||||
|
pN0 pN + |
32 (84.2%) 06 (15.8%) |
18 (69.2%) 08 (30.8%) |
0.155 |
29 (82.9%) 06 (17.1%) |
21 (72.4%) 08 (27.6%) |
0.314 |
| Malignancy grading | ||||||
|
More differentiated Less differentiated |
38 (76.0%) 12 (24.0%) |
31 (83.8%) 06 (16.2%) |
0.376 |
34 (73.9%) 12 (26.1%) |
35 (85.4%) 06 (14.6%) |
0.188 |
#Excluding patients with lost records